HGS Sues Genentech To Protect Lupus Drug

Law360, New York (January 27, 2011, 2:39 PM EST) -- Human Genome Sciences Inc. has filed suit against Genentech Inc. and cancer center City of Hope, seeking a declaration that a patent assigned to the defendants is invalid and not infringed by lupus drug Benlysta.

HGS expects a decision from the U.S. Food and Drug Administration regarding the approval of its Biologic License Application for Benlysta in the near future, according to a complaint the company filed in the U.S. District Court for the District of Delaware on Tuesday.

Upon approval, HGS intends to start marketing...
To view the full article, register now.